The collaboration improves CGT manufacturing through a standardized, scalable platform

College Station, TX and Woodcliff Lake, New Jersey – November 17, 2020 – G-CON Manufacturing, Inc. (G-CON), a leader in prefabricated flexible cleanroom solutions, and Ori Biotech Ltd. (Ori), an innovator in cell and gene therapy (CGT) manufacturing, announced today their global collaboration to offer a predesigned platform for flexible manufacturing of cell therapies. The non-exclusive collaboration integrates Ori’s proprietary, flexible CGT manufacturing platform with the highly innovative prefabricated cleanroom that is the G-CON POD. The combination of the two technologies will provide standardized CGT manufacturing in a closed platform that can be seamlessly scaled for clinical through commercial scale manufacturing.

Ori’s ability to increase throughput, improve quality and decrease cost coupled with G-CON’s extensive experience in building cGMP manufacturing facilities for various modalities will combine to achieve the ultimate goal to help therapy developers bring lifesaving therapies to patients more quickly and cost effectively.

“G-CON is a leader in flexible cell and gene therapy manufacturing and, with this collaboration, Ori continues to partner with best-in-class, expert suppliers across the CGT ecosystem. This partnership will help enable our vision for a fully integrated, automated, closed system manufacturing platform supporting the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Innovation that reduces the significant size and cost of cell and gene therapy manufacturing facilities to enable scalable capacity, distributed manufacturing and marks another step toward enabling our partners to bring their life saving treatments to patients at scale.”

“A significant, upfront investment of $50M-$150M is often required to develop manufacturing capacity and building large bricks and mortar manufacturing facilities presents major challenges for CGT developers. An Ori powered G-CON POD can provide a flexible model with rapid scalability to manufacture thousands of doses of advanced therapies in a much smaller footprint, reducing the required facility investment by up to 75%” added Jason C. Foster, CEO, Ori Biotech.

”Ori is a pioneer in the cell therapy field with a truly disruptive technology in development,” said Peter Makowenskyj, Director of Sales Engineering for G-CON. “Enhancing automation and closing the process really eliminates a lot of the high cost elements and manual interventions currently required in making cell therapies. Our collaboration aligns well with Pharma 4.0 initiatives along with distributed manufacturing and will ultimately bring these treatments to patients more quickly and cost effectively.”

About G-CON Manufacturing

G-CON Manufacturing designs, builds and installs prefabricated G-CON POD® cleanrooms. G-CON’s POD portfolio provides cleanrooms in a number of dimensions for a variety of uses, from laboratory environments to personalized medicine and production process platforms. G-CON POD® cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end. For more information, please visit G-CON’s website at http://www.gconbio.com.

About Ori Biotech

Ori is a London and New Jersey based cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes CGT manufacturing allowing therapeutics developers to further develop and bring their products to market at commercial scale. The promise of the full stack Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs by combining hardware, software and data services.

Ori was founded by Professor Chris Mason (AVRO) and Dr. Farlan Veraitch (UCL) and has brought together a seasoned Board and executive management team with over 100 years of pharmaceutical, CGT and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec), VP Tom Heathman (HCATS) alongside expert advisers like Bruce Levine, Anthony Davies and Bob Preti.

Syndicate led by leading life science investors Northpond Ventures alongside Octopus Ventures

October 14, 2020, London, UK and Woodcliff Lake, NJ – Ori Biotech Ltd (Ori), a leading innovator in cell and gene therapy (CGT) manufacturing, today announced the successful close of a $30 million Series A financing round, bringing the company’s total funding to date to $41 million. The new funding will be used to help bring Ori’s innovative manufacturing platform to the market. The Ori platform delivers scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.

The Series A investor syndicate was led by the experienced life sciences investment team at Northpond Ventures, a leading global science, medical, and technology-driven venture fund, alongside Octopus Ventures, a leading European venture fund. Northpond and Octopus invested alongside significant support from Ori’s existing institutional investors,  Amadeus Capital Partners, Delin Ventures and Kindred Capital.

“Closing a significant Series A round, during these uncertain times, further validates Ori’s disruptive approach to fully automating cell and gene therapy manufacturing to increase throughput, improve quality and decrease costs,” said Jason C. Foster, CEO of Ori Biotech. “We are excited to work with our top tier investors and development partners to bring our platform to market as fast as possible to achieve our mission of enabling patient access to life-saving cell and gene therapies.”

“As early investors in disruptive life sciences platform technology companies, we have seen how cutting-edge technologies like Ori’s can bring significant value to the industry and lead to breakthroughs for patients,” said Michael Rubin, M.D., Ph.D., Founder and CEO of Northpond Ventures. “We believe that the Ori team has developed a truly innovative technology that can enable millions of patients to gain access to these important treatments.”

Ori’s bespoke platform was designed specifically to address the unique requirements of a new generation of personalized cell and gene therapies. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial-scale manufacturing. Its flexible platform enables increased throughput, improved quality and decreased costs.

“This new funding will allow us to continue addressing the significant challenges of providing high throughput, high quality and cost-effective CGT manufacturing and to bring our novel platform into the clinic as quickly as possible to support the important work of our therapeutic developer partners,” added Dr. Farlan Veraitch, Co-Founder and Chief Scientific Officer of Ori Biotech.

About Ori Biotech

Ori Biotech is a London and New Jersey based cell and gene therapy (CGT) manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardizes manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial-scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of life-saving treatments. Ori was founded in 2015 by Dr. Farlan Veraitch and Professor Chris Mason. The company has brought together a seasoned board and executive management team with over 100 years of pharmaceutical, cell therapy and venture building experience, including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec) and Tom Heathman (HCATS) alongside industry-leading expert advisors like Bruce Levine, Annalisa Jenkins and Anthony Davies.

About Northpond Ventures

Northpond Ventures is a global science, medical, and technology focused venture capital firm, with offices in Bethesda, Cambridge, and San Francisco. Northpond has in excess of $1 billion of committed capital. Our mission is to build a better tomorrow. Learn more at: npv.vc.

For more information, contact:

Katie Marggraf
BAM the Agency
katie@bamtheagency.com
858-284-7768

Philadelphia, US and London UK, July 28, 2020 – Ori Biotech Ltd (Ori) is pleased to announce the appointment of Thomas Heathman, PhD as their new Vice President of Commercial Operations for North America. Dr Heathman has over 10 years’ experience in the cell and gene therapy (CGT) industry and a deep understanding of cGMP manufacturing for CGT products. He will join Ori on September 7, 2020.

Prior to this, Dr Heathman served as the Business Leader for North America for Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a leading Contract Development and Manufacturing Organization for the CGT industry. During his time with HCATS, he led the unprecedented growth of the North America business including the recent signing of a commercial manufacturing agreement with bluebird bio. In addition to managing the North America region, he also served as the Global Head of Technology within HCATS in charge of evaluating and deploying new technologies, and played an instrumental role in the signing of a Joint Development Agreement between Ori and HCATS which was announced in January 2020.

In accepting this appointment, Dr Heathman stated “Ori’s innovative technology provides the industry the opportunity to solve the scalability challenges that currently face CGT manufacturing. The flexible platform that Ori has developed, specifically for cell and gene therapy, has the potential to transform the manufacturing of this new class of personalized medicines. Ori’s mission to enable patient access to life saving treatments inspired me to join their world-class team and I am honored to lead a North America region focused on close collaboration with Ori’s partners and customers.”

Farlan Veraitch, Founder and Chief Scientific Officer, said, “We are delighted to have Tom join us to lead commercial operations for North America. His deep experience in CGT manufacturing, combined with his demonstrated ability to lead and grow organizations, will ensure Ori is best placed to be the preferred technology partner for the CGT industry.” Jason C. Foster, Chief Executive Officer, added, “Tom’s deep understanding of the manufacturing needs of CGT product developers will help us build a world-class organization to support our partners in providing widespread access for patients to life saving cell and gene therapies.”

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior), CBO Jason Jones (Miltenyi Biotec) and Tom Heathman (HCATS) alongside industry-leading expert advisors like Bruce Levine, Annalisa
Jenkins and Anthony Davies.

For more information contact:

Ori Biotech
Jason C. Foster
CEO
jasonfoster@oribiotech.com

Philadelphia, PA and Ormond Beach, FL – June 15, 2020 – Ori Biotech Ltd (Ori), an innovator in cell and gene therapy (CGT) manufacturing, and Germfree Laboratories Inc (Germfree), experts in providing process-ready, mobile and modular cleanrooms for CGT manufacturing today announced a collaboration partnership to create an intensified, manufacturing platform that will facilitate higher throughput in both centralized and decentralized CGT manufacturing models.

“Ori Biotech continues to build partnerships with best-in-class expert suppliers across the cell and gene therapy ecosystem, like Germfree, to help enable our vision for a fully integrated, closed system manufacturing platform supporting the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Innovation that reduces the significant size and cost of cell and gene therapy manufacturing facilities is another step toward enabling our customers to bring their life saving treatments to patients at scale.”

“Germfree has a long history of developing cleanroom technologies for specific applications based on tractor trailer and modular building platforms,” said Kevin Kyle, President, Germfree. “We are excited to be partnering with a ground-breaking company like Ori Biotech to deliver the vision of vein-to-vein point of care for personalized medicine delivery.”

“With cost of building bricks and mortar manufacturing facilities reaching $50M-$100M, an Ori powered Germfree mobile or modular manufacturing unit could provide the capability to manufacture thousands of doses of an individual advanced therapy in a much smaller footprint which could reduce the upfront investment required by up to 75%” added Jason C. Foster, CEO, Ori Biotech.

About Germfree

Germfree creates environments that serve life science innovation and advance global health. Germfree designs and manufactures flexible cGMP-compliant cleanroom buildings and high-containment facilities which are process or containment-ready upon deployment. Our facilities are designed to integrate with Germfree’s core equipment including our lines of interchangeable laminar flow hoods and containment equipment. Established in 1962 Germfree’s leading-edge fabrication technology, engineering teams and subject-matter experts are located at our 173,000 square foot (16,000 square meter) US manufacturing plant. Visit our website www.germfree.com for more information or contact us at media@germfree.com.

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine, Anthony Davies and Annalisa Jenkins.

For more information contact:

Germfree
Four Sunshine Blvd
Ormond Beach
Florida 32174, USA
Tel: +1 386-265-4360
Contact Email: media@germfree.com

Ori Biotech
Jason C. Foster
CEO
jasonfoster@oribiotech.com

Freiburg, Germany and London, UK, May 13, 2020 – Ori Biotech Ltd, (Ori), an innovator in cell and gene therapy (CGT) manufacturing and CellGenix GmbH, a leading global supplier of high quality raw and ancillary materials for CGT and regenerative medicine, announced today a non-exclusive strategic partnership to achieve closed-system preparation, formulation and addition of CellGenix media and growth factors within CGT manufacturing for users of the Ori platform.

The Ori platform enables therapy developers and contract manufacturers to achieve more automated, more efficient CGT manufacturing in a closed system. Utilising innovations from both Ori and CellGenix, users of the Ori manufacturing platform can eliminate process bottlenecks and open steps in media and growth factor formulation, preparation and transfers in order to enable higher throughput and reduced costs by eliminating manual handling steps. Ori selected CellGenix’ raw material portfolio as a partner because of its high quality standards and over 25 years of experience. CellGenix are experts in GMP manufacturing of raw materials which offer the highest quality and safety.

“Ori Biotech is continuing to build partnerships with best-in-class experts across the cell and gene therapy ecosystem to help enable our vision of integrated, closed system manufacturing,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “Innovation around the integration of high-quality materials from CellGenix into the Ori full-stack platform is another step toward enabling our customers to have a fully-closed manufacturing process from end-to-end, removing bottlenecks in formulation, preparation and process flow.”

“We are always interested in bringing the CGT industry forward by exploring innovative solutions that help simplify the production process as well as reduce the costs of goods”, said Felicia M. Rosenthal, CEO, CellGenix. “In addition to developing and producing our widely used raw materials and proprietary media solutions, we are building partnerships with companies developing next generation automated cell and gene therapy manufacturing platforms like Ori Biotech.” Till Puschmann, VP R&D and Business Development, CellGenix added “Through this collaboration our two companies will be able to offer our joint customers an innovative closed-system manufacturing platform including the necessary high-quality raw materials.”

“Through our ecosystem partnerships, we hope to provide our customers with integrated solutions that take some of the hassles out of their supply chain and manufacturing processes to allow them to focus on what they do best, delivering life-saving treatments to the patients who need them,” added Jason C. Foster, CEO, Ori Biotech.

About CellGenix

CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. CellGenix develops, manufactures and markets human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as proprietary serum-free media for further manufacturing of ATMPs. As an ATMP developer and manufacturer, CellGenix gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background, CellGenix understands the high requirements their customers face during product development and the regulatory approval process. To meet the increasing demand for GMP quality raw materials for ATMP manufacturing CellGenix has recently expanded manufacturing capacity, built additional R&D and QC laboratories, and warehouse space. The upgrade also introduced state-of-the-art, automated, large-scale capacities for recombinant protein products in the existing GMP facilities. CellGenix is headquartered in Freiburg, Germany and operates a subsidiary near Boston in Portsmouth, USA.
https://cellgenix.com/

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing. The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine, Anthony Davies and Annalisa Jenkins.

For more information contact:

CellGenix
Am Flughafen 16
79108 Freiburg, Germany
Felicia M. Rosenthal
CEO
rosenthal@cellgenix.com

Ori Biotech
Jason C. Foster
CEO
jasonfoster@oribiotech.com

London UK, April 14, 2020 – Today Ori Biotech Ltd (Ori) an innovator in cell and gene therapy (CGT) manufacturing announced a partnership with Achilles Therapeutics (Achilles) to test the application of Ori’s novel manufacturing technology to Achilles’ manufacturing process.

High quality, low cost, high throughput cell and gene therapy manufacturing continues to be a significant challenge for the industry. The resulting variability and high cost of goods are contributing to the current lack of wide-spread patient access to this new generation of life-saving treatments. Therapeutics developers, regulators and technology providers are all seeking to identify innovative approaches for efficient product manufacturing.

“The team at Ori are excited to partner with innovative companies like Achilles who want to address manufacturing early in their lifecycle so that they can quickly bring their products to patients at scale,” said Jason C. Foster, CEO Ori Biotech. “We believe that collaborating with therapy developers early is key to maximizing the scalability and repeatability of these often-complicated manufacturing processes.”

“Achilles is excited to start testing the Ori manufacturing platform in our proprietary clonal neoantigen T-cell (cNeT) therapy manufacturing process,” said Ed Samuel, SVP Manufacturing, Achilles Therapeutics. “Achilles is at a transformational stage in its development with the recent initiation of our first-in-human clinical studies. By harnessing the immune system to destroy cancer cells our cNeT therapy platform could fundamentally change how cancer is treated. Looking to emerging technologies to support our long-term strategy for a fully automated manufacturing process is central to Achilles’ plans for scaling up our production capabilities to deliver personalized cell therapies.”

Farlan Veraitch, Co-Founder and CSO, Ori Biotech added

“It is always great to work with the forward-thinking leaders in cell and gene therapy, like Achilles, who are focused on innovating across the board, not just clinically and scientifically but also technologically. We see huge potential for the future of this partnership.”

For more information, contact:

Ori Biotech
Jason C. Foster
CEO
jasonfoster@oribiotech.com

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine, Anthony Davies and Annalisa Jenkins.

Cardiff and London UK, February 25, 2020 – TrakCel, a leading software developer for cell and gene therapy supply chain tracking and orchestration systems, and Ori Biotech Ltd, (Ori), an innovator in cell and gene therapy (CGT) manufacturing, announce today a non-exclusive strategic partnership to achieve supply chain orchestration within closed system manufacturing for the cell and gene therapy sector.

The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed platform.  The collaboration will enable users of the Ori Biotech manufacturing platform to benefit from live supply chain visibility through TrakCel software and TrakCel customers to have greater visibility into the manufacturing process via data services within the Ori platform.  Resulting from the agreement, TrakCel and Ori will develop suitable points of integration in order for a shared data platform to be available to partners.

“TrakCel has developed an extensive partnership network with contract manufacturers and companies across the cell and gene therapy sector. This enables therapeutic developers to be supported by more standardized and integrated solutions,” said Fiona Withey, Co-Founder and CEO, TrakCel. “Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.”

“Ori Biotech is continuing to build a network of best-in-class partners across the cell and gene therapy ecosystem to help enable our provision of integrated, closed system manufacturing to the cell and gene therapy industry,” said Farlan Veraitch, Co-Founder and CSO, Ori Biotech. “The integration of TrakCel’s advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.”

For more information, contact:

TrakCel
Image Box PR
Neil Hunter / Michelle Boxall
Tel: +44 (0) 20 8943 4685
michelle@imageboxpr.co.uk

Ori Biotech
Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
Optimum Communications
+44 20 3922 0891
oribiotech@optimumcomms.com

About TrakCel

TrakCel is the market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. https://trakcel.com

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.

January 21, 2020 – Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and manufacturing development of cell therapy products, and Ori Biotech Ltd. (Ori), an innovator in cell and gene therapy (CGT) manufacturing, today announced they have entered into a joint development agreement to develop and commercialize technology solutions specific to the cell and gene therapy industry. Combining HCATS’ decades of experience in manufacturing and development with Ori Biotech’s proprietary technology platform and innovative approach allows both parties to better address the increasingly critical manufacturing needs of cell and gene therapy developers.

“We are very excited to announce our collaboration with Ori Biotech,” said Robert Preti, Ph.D., President and CEO HCATS, General Manager, Regenerative Medicine Business Sector, Hitachi Chemical. “Using our 20 years of manufacturing experience to help advance Ori’s novel technology furthers our leadership in addressing the industry’s manufacturing challenges and accelerates the process of delivering our clients’ therapeutics to patients in need. We look forward to partnering with Ori and are confident this collaboration will help drive innovation throughout the industry.”

“Our partnership with HCATS provides us an exciting opportunity to further develop and tailor our innovative CGT manufacturing platform technology for use in the real world,” said Jason C. Foster, CEO of Ori Biotech. “Leveraging HCATS longstanding experience in cell and gene therapy manufacturing helps us progress our technology much faster than we could on our own as we both work to bring the next generation of manufacturing solutions to market.  Partnering with such a renowned and experienced contract manufacturer will help demonstrate the potential of our platform to address the significant challenges in large-scale production of these life-saving therapies.”

For more information, contact:

Hitachi Chemical Advanced Therapeutics Solutions, LLC
Gregory Johnson
gregory.johnson.jt@hitachi-chem.com
Tel: +1 201 515 2153

Ori Biotech
Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
Optimum Communications
+44 20 3922 0891
oribiotech@optimumcomms.com

About Hitachi Chemical Advanced Therapeutics Solutions

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS, formerly PCT Cell Therapy Services, LLC), is a wholly owned subsidiary of Hitachi Chemical Company, Ltd. (Hitachi Chemical) representing Hitachi Chemical’s Regenerative Medicine Business Sector in the United States. HCATS leverages two decades of experience exclusively focused on the cell therapy industry. It provides contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. Facilities to deliver these services have been established in New Jersey and California, with an expansion to add commercial manufacturing capabilities and capacity underway in New Jersey. Furthermore, the Hitachi Chemical Regenerative Medicine Business Sector includes capabilities in Asia (Yokohama, Japan) and Europe (Munich, Germany). For more information about these services, please visitwww.pctcelltherapy.com

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.

Syndicate includes leading UK investors Amadeus Capital Partners, Delin Ventures and Kindred Capital Appoints Jason C. Foster as Chief Executive Officer

January 8, 2020, London, UK and Philadelphia, USA – Ori Biotech Ltd (Ori), an innovator in Cell and Gene Therapy (CGT) manufacturing, today announced that they successfully closed a $9.4M (£7M) Seed Round which will be used to bring their innovative manufacturing platform to market. The Ori platform will deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.

Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, Ori has designed a bespoke platform to specifically address the unique requirements of the new generation of personalised, living medicines. The investor syndicate is comprised of some of the UK’s leading venture investors including Amadeus Capital Partners, Delin Ventures, Kindred Capital and a London-based family office, alongside a group of angel investors who have supported the company since inception.

Jason C. Foster, newly appointed CEO of Ori Biotech said: “The successful financing underscores the potential of the Ori platform to fully automate cell and gene therapy manufacturing to increase throughput, improve quality and decrease costs. We look forward to collaborating with best-in-class suppliers, service providers and therapeutics developers to create next generation manufacturing solutions.  We appreciate the support from our investors, and I am honored to join a company that has the potential to positively impact millions of lives by enabling patient access to these lifesaving treatments.”

“Hundreds of clinical trials and a few recently marketed products have shown the revolutionary potential of CGTs. But this potential will never be realised unless we can remove the current bottleneck around scalable manufacturing. Ori Biotech has developed an innovative platform technology to facilitate scalable manufacturing that could eventually enable millions of patients to get access to the next generation of personalised medicines,” commented Dr Alan Barge, ex-Head of Oncology at AstraZeneca, Venture Partner at Delin Ventures and Non-Executive Director of Ori Biotech.

Dr Farlan Veraitch, Co-Founder and Chief Scientific Officer of Ori Biotech added, “The challenges of providing high throughput, high quality and cost-effective CGT manufacturing are well documented in the industry and in publications by global regulatory authorities like the US FDA. By pioneering a completely novel hardware and software approach, we can help the CGT industry accelerate the delivery of these transformative therapies to patients in need.”

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.

For more information, contact:

Ori Biotech
Jason C. Foster, CEO
jasonfoster@oribiotech.com

Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 0891
oribiotech@optimumcomms.com

December 4, 2019, London, UK – Ori Biotech Ltd (Ori), a London- and Philadelphia-based innovator in Cell and Gene Therapy (CGT) manufacturing, has been selected to participate in the London Mayor’s International Business Programme (MIBP), which showcases some of the most innovative companies in London. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, Ori has designed a bespoke platform to specifically address the unique requirements of the new generation of personalised, living medicines. Helping to deliver scalable solutions to flexibly address the critical clinical and commercial manufacturing needs of CGT developers.

As part of MIBP, Ori will act as an ambassador for the UK advanced therapies community on international trade missions. In line with the UK Government’s Industrial Strategy, CGTs – and technologies that enable their widespread access – have significant potential as a new source of economic growth according to the Advanced Therapies Manufacturing Taskforce. It was set up to identify actions that the UK must consider taking in order to anchor manufacturing of advanced therapies and capture investments to secure the UK’s position as a world-class hub.

“We have seen rapid growth and significant clinical success with advanced therapies in recent years and the UK has been at the forefront of this research and development. The sector is moving quickly and is now at a critical point, as it prepares to commercialise and scale up manufacture of these treatments,” wrote Ian McCubbin, Chair of Medicines Manufacturing Industry Partnership in the Advanced Therapies Manufacturing Action Plan Report.1 The report stated that, “The UK is very well placed to anchor manufacturing of these potentially curative therapies in the UK and secure its position as a global hub for advanced therapies but the time to act is now. The forthcoming Industrial Strategy gives us an opportunity to take forward this report and work together to secure investments, further the science, and contribute significant benefits to the UK economy and patients in the UK and worldwide.”1

About Ori Biotech

Ori Biotech is a London- and Philadelphia-based CGT manufacturing technology company. Ori has developed a proprietary, flexible manufacturing platform that closes, automates and standardises manufacturing allowing therapeutics developers to further develop and bring their products from pre-clinical process development to commercial scale manufacturing.

The mission of the Ori platform is to fully automate CGT manufacturing to increase throughput, improve quality and decrease costs in order to enable patient access to this new generation of lifesaving treatments. Founded by Dr Farlan Veraitch and Prof Chris Mason in 2015, the Company has brought together a seasoned Board and executive management team with over 80 years of pharmaceutical, cell therapy and venture building experience including CEO Jason C. Foster (Indivior) and CBO Jason Jones (Miltenyi Biotec) alongside industry-leading expert advisors like Bruce Levine and Anthony Davies.

For more information, contact:

Ori Biotech
Jason C. Foster, CEO
jasonfoster@oribiotech.com

Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 0891
oribiotech@optimumcomms.com